Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30275569.
- Also identified by DOI 10.1038/s41591-018-0146-z.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19<sup>-</sup> relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority of resistant tumor cells and are predicted to lead to a truncated protein with a nonfunctional or absent transmembrane domain and consequently to a loss of surface antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination CAR approach.
Medical subject headings
- Drug Resistance, Neoplasm
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Receptors, Antigen, T-Cell
- Receptors, Chimeric Antigen